Drug intelligence / Profile preview

MacTel2 program

Development stage: Preclinical
Lead developer: Scenic Biotech
Administration: Intravitreal, Oral

Overview

The MacTel2 program is a drug discovery initiative by Scenic Biotech aimed at treating Macular Telangiectasia Type 2 (MacTel2), a rare degenerative retinal disease. The program leverages Scenic's proprietary Cell-Seq platform to identify genetic modifiers—genes that, when inhibited or activated, can suppress the disease-causing effects of primary genetic mutations or metabolic imbalances. While the specific targets and therapeutic modalities (such as small molecules or antisense oligonucleotides) remain undisclosed, the research focuses on addressing the underlying pathology of MacTel2, which is often linked to serine deficiency and the accumulation of neurotoxic deoxysphingolipids.

Other names: Scenic Biotech MacTel2 program

Beyond the preview

Go deeper on MacTel2 program.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MacTel2 program.

Explore the full profile